Drug Profile

JV 001

Alternative Names: JV-001

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Juvensis Therapeutics Biotechnology
Class Gene therapies; Heart failure therapies; Recombinant proteins
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Heart failure

Most Recent Events

28 May 2026 No recent reports of development identified for phase-0 development in Heart-failure(Treatment-experienced) in China (Intracoronary, Infusion)
11 Nov 2023 Pharmacodynamics data from preclinical studies in Heart failure presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
06 Apr 2023 Phase-0 for Heart failure (Treatment-experienced) in China (Intracoronary) (NCT05837143)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com